Genomic Characterisation of Virulence and In Vivo Pathogenicity of Azole-Antifungal Resistant Candida from HIV/AIDS Patients in Southeast Nigeria
Article Sidebar
Main Article Content
Abstract
Background: Oral candidiasis remains a common opportunistic infection among people living with HIV/AIDS, especially in low-resource settings. Rising antifungal resistance and systemic candidiasis complicate treatment. This study investigated the genomic features and virulence mechanisms of Candida species isolated from HIV-positive individuals in southeast Nigeria.
Methods: Oral swabs (n=514) from HIV patients were collected and cultured on Chromogenic agar for Candida, with azole susceptibility assessed through the Kirby-Bauer disk-diffusion method. Representative isolates underwent whole-genome sequencing to identify virulence genes and mechanisms. A pathogenicity study was conducted on 16 rats, divided into four groups: Candida albicans, Candida glabrata, a mixed inoculum, and a non-inoculated control. Over 28 days, morbidity, mortality, weight changes, and organ infections were evaluated.
Results: All sequenced strains belonged to Sequence Type 15 with conserved genomes. Key virulence genes (waaF, waaG, pilH, and pvdS) and housekeeping genes (argS, gyrB, ileS, nuoC, ppsA, recA, rpoB, rpoD) were consistently expressed, supporting biofilm formation, stress tolerance, immune evasion, and persistence mechanisms. In vivo, rats inoculated with C. albicans or mixed inoculum showed severe morbidity, high mortality (100% and 75% respectively), weight loss, and tissue necrosis, indicating systemic infection.
Conclusion: Azole-resistant Candida species from HIV-infected individuals exhibit diverse genetic and phenotypic mechanisms that drive virulence and resistance. The findings emphasise their pathogenic potential and the challenges they pose for diagnosis and treatment. Genomic similarity among isolates indicates clonal expansion and potential interspecies gene exchange, underscoring the importance of integrated antifungal surveillance and stewardship in resource-limited settings.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Journal is owned, published and copyrighted by the Nigerian Medical Association, River state Branch. The copyright of papers published are vested in the journal and the publisher. In line with our open access policy and the Creative Commons Attribution License policy authors are allowed to share their work with an acknowledgement of the work's authorship and initial publication in this journal.
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author.
The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations. While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
TNHJ also supports open access archiving of articles published in the journal after three months of publication. Authors are permitted and encouraged to post their work online (e.g, in institutional repositories or on their website) within the stated period, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). All requests for permission for open access archiving outside this period should be sent to the editor via email to editor@tnhjph.com.
How to Cite
References
1.Suryana K, Suharsono H, Antara IG. Factors associated with oral candidiasis in people living with HIV/AIDS: a case control study. HIV/AIDS-Research and Palliative Care. 2020:33-9. https://doi.org/10.2147/HIV.S236304
2.Vila T, Sultan AS, Montelongo-Jauregui D, Jabra-Rizk MA. Oral candidiasis: A disease of opportunity. Journal of fungi. 2020;6(1):15. https://doi.org/10.3390/jof6010015
3.Taylor, M., Brizuela, M., and Raja, A.) Oral candidiasis. In: StatPearls. Treasure Island (FL): Stat Pearls Publishing 2023.
4.Bilal H, Shafiq M, Hou B, Islam R, Khan MN, Khan RU, Zeng Y. Distribution and antifungal susceptibility pattern of Candida species from mainland China: a systematic analysis. Virulence. 2022;13(1):1573-89.
5.Ekwealor CC, Nweke CJ, Anaukwu CG, Anakwenze VN, Ogbukagu CM, Mba AN. Prevalence and antifungal susceptibility pattern of oral candidiasis among HIV-infected patients in a Mission Hospital, southeast Nigeria. African Journal of Clinical and Experimental Microbiology. 2023;24(3):289-98.
6.Rodríguez-Cerdeira C, Gregorio MC, Molares-Vila A, López-Barcenas A, Fabbrocini G, Bardhi B, Sinani A, Sánchez-Blanco E, Arenas-Guzmán R, Hernandez-Castro R. Biofilms and vulvovaginal candidiasis. Colloids and Surfaces B: Biointerfaces. 2019;174:110-25.
7.Wall G, Montelongo-Jauregui D, Bonifacio BV, Lopez-Ribot JL, Uppuluri P. Candida albicans biofilm growth and dispersal: contributions to pathogenesis. Current opinion in microbiology. 2019 Dec 1;52:1-6.
8.Rolo J, Faria-Gonçalves P, Barata T, Oliveira AS, Gaspar C, Ferreira SS, Palmeira-de-Oliveira R, Martinez-de-Oliveira J, Costa-de-Oliveira S, Palmeira-de-Oliveira A. Species distribution and antifungal susceptibility profiles of isolates from women with nonrecurrent and recurrent vulvovaginal candidiasis. Microbial Drug Resistance. 2021;27(8):1087-95.
9.Favour EE, Oroboghae OH, Pius OO, Gidion EE. Epidemiology of Oral Candida Infection among People Living With HIV/AIDS (PLWHA) in Bida, Niger State, Nigeria. Sokoto Journal of Medical Laboratory Science. 2017;2(3).
10.Hu L, He C, Zhao C, Chen X, Hua H, Yan Z. Characterization of oral candidiasis and the Candida species profile in patients with oral mucosal diseases. Microbial pathogenesis. 2019 Sep 1;134:103575.
11.Akamike IC, Okedo-Alex IN, Agu AP, Alo C, Ogbonnaya LU. Knowledge and adherence to isoniazid preventive therapy among people living with HIV in multilevel health facilities in South-East, Nigeria: baseline findings from a quasi-experimental study. Pan African Medical Journal. 2020;36(1).1-11
12.Neppelenbroek KH, Seó RS, Urban VM, Silva S, Dovigo LN, Jorge JH, Campanha NH. Identification of Candida species in the clinical laboratory: a review of conventional, commercial, and molecular techniques. Oral diseases. 2014;20(4):329-44.
13.Cheesbrough, M. (2010). District laboratory practice in tropical countries. 2nd edition.
14.Clinical Laboratory Standard Institute (CLSI) Performance Standards for antimicrobial susceptibility testing. Twentieth information supplement (M100 – S20). 9th edition. Clinical Laboratory Standard Institute, Wayne. 2010:1- 253.
15.Zymo Research. Quick-DNA Fungal/Bacterial Kits. 2025. https://www.zymoresearch.com/collections/quick-dna-fungal-bacterial-kits?srsltid=AfmBOooYh0pmhgPkohsksLU09ce8UFDfO-NWF17Ib3vmIT7Bz-kIXyC9
16.Yamamoto N, Dannemiller KC, Bibby K, Peccia J. Identification accuracy and diversity reproducibility associated with internal transcribed spacer‐based fungal taxonomic library preparation. Environmental microbiology. 2014;16(9):2764-76.
17.Zuo Y, Verheecke-Vaessen C, Molitor C, Medina A, Magan N, Mohareb F. De novo genome assembly and functional annotation for Fusarium langsethiae. BMC genomics. 2022;23(1):158.
18.Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. PLoS computational biology. 2017 Jun 8;13(6):e1005595.
19.Gurevich A, Saveliev V, Vyahhi N, Tesler G. QUAST: quality assessment tool for genome assemblies. Bioinformatics. 2013;29(8):1072-5.
20.Liu B, Zheng D, Jin Q, Chen L, Yang J. VFDB 2019: a comparative pathogenomic platform with an interactive web interface. Nucleic acids research. 2019;47(D1):D687-92.
21.Alcock BP, Raphenya AR, Lau TT, Tsang KK, Bouchard M, Edalatmand A, Huynh W, Nguyen AL, Cheng AA, Liu S, Min SY. CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database. Nucleic acids research. 2020;48(D1):D517-25.
22.Wattam AR, Abraham D, Dalay O, Disz TL, Driscoll T, Gabbard JL, Gillespie JJ, Gough R, Hix D, Kenyon R, Machi D. PATRIC, the bacterial bioinformatics database and analysis resource. Nucleic acids research. 2014;42(D1):D581-91.
23.Hirayama T, Miyazaki T, Ito Y, Wakayama M, Shibuya K, Yamashita K, Takazono T, Saijo T, Shimamura S, Yamamoto K, Imamura Y. Virulence assessment of six major pathogenic Candida species in the mouse model of invasive candidiasis caused by fungal translocation. Scientific reports. 2020;10(1):3814.
24.Shadkchan Y, Shemesh E, Mirelman D, Miron T, Rabinkov A, Wilchek M, Osherov N. Efficacy of allicin, the reactive molecule of garlic, in inhibiting Aspergillus spp. in vitro, and in a murine model of disseminated aspergillosis. Journal of Antimicrobial Chemotherapy. 2004 May 1;53(5):832-6.
25.Software. "Tableau Desktop." Tableau Software. 2020. https://www.tableau.com
26.Metsalu T, Vilo J. ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. Nucleic acids research. 2015;43(W1):W566-70.
27.Van Rossum, G., & Drake, F. L. Python 3 Reference Manual. CreateSpace, 2009. https://www.python.org
28.Mannweiler O, Pinto-Carbó M, Lardi M, Agnoli K, Eberl L. Investigation of Burkholderia cepacia complex methylomes via single-molecule, real-time sequencing and mutant analysis. Journal of Bacteriology. 2021;203(12):10-128.
29.Kumar A, Francis A, Hans S, Thakur A. Unravelling Drug Resistance in Candida Species: Genetic, Biofilm, Transcriptional, and Epigenetic Perspectives. InRecent Advances in Human Fungal Diseases: Progress and Prospects 2024:203-237).
30.Garcia-Vello P, Di Lorenzo F, Zucchetta D, Zamyatina A, De Castro C, Molinaro A. Lipopolysaccharide lipid A: A promising molecule for new immunity-based therapies and antibiotics. Pharmacology & therapeutics. 2022; 230:107970.
31.Anderson MZ, Saha A, Haseeb A, Bennett RJ. A chromosome 4 trisomy contributes to increased fluconazole resistance in a clinical isolate of Candida albicans. Microbiology. 2017;163(6):856-65.
32.Sanglard D, Coste AT. Activity of isavuconazole and other azoles against Candida clinical isolates and yeast model systems with known azole resistance mechanisms. Antimicrobial agents and chemotherapy. 2016;60(1):229-38.
33.Oliveira F, Lima T, Correia A, Silva AM, Soares C, Morais S, Weißelberg S, Vilanova M, Rohde H, Cerca N. Siderophore-mediated iron acquisition plays a critical role in biofilm formation and survival of Staphylococcus epidermidis within the host. Frontiers in Medicine. 2021 Dec 24; 8:799227.
34.Geiger CJ, Wong GC, O'Toole GA. A bacterial sense of touch: T4P retraction motor as a means of surface sensing by Pseudomonas aeruginosa PA14. Journal of Bacteriology. 2024 Jul 25; 206(7):e00442-23.
35.Nishimoto AT, Zhang Q, Hazlett B, Morschhäuser J, Rogers PD. Contribution of clinically derived mutations in the gene encoding the zinc cluster transcription factor Mrr2 to fluconazole antifungal resistance and CDR1 expression in Candida albicans. Antimicrobial Agents and Chemotherapy. 2019 May; 63(5):10-128.
36.Staniszewska M. Virulence factors in Candida species. Current Protein and Peptide Science. 2020;21(3):313-23.